^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    ROR1 inhibitor

    Related drugs:
    2ms
    A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    nebratamig (GNC-035)
    2ms
    GNC-035-103: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    nebratamig (GNC-035)
    2ms
    A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=3, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=40 --> 3
    Enrollment closed • Enrollment change
    |
    nebratamig (GNC-035)
    2ms
    A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=58 --> 33
    Enrollment closed • Enrollment change
    |
    nebratamig (GNC-035)
    3ms
    GNC-035-103: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=29, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    nebratamig (GNC-035)
    3ms
    A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    nebratamig (GNC-035)
    3ms
    A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov)
    P1, N=58, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    nebratamig (GNC-035)
    4ms
    PBL-0405-01: A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=8, Completed, Pure Biologics S.A. | Recruiting --> Completed
    Trial completion
    6ms
    NM32-2668 in Adult Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=11, Terminated, Numab Therapeutics AG | N=180 --> 11 | Trial completion date: Dec 2027 --> Apr 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2027 --> Apr 2025; Business decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    6ms
    Optimization of 1-Methyl-3-(pyridin-3-yl)-1H-indol Derivatives as ROR1 Inhibitors with Improved Activity and Selectivity. (PubMed, J Med Chem)
    This effort produced a series of 1-methyl-3-(pyridin-3-yl)-1H-indole derivatives, culminating in the discovery of compound 24d. This lead candidate demonstrates exceptional ROR1 inhibitory potency, high selectivity, robust antitumor activity in vitro and in vivo, and an optimized PK profile, marking a substantive advance toward selective ROR1 inhibitors.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    7ms
    NM32-2668 in Adult Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Active, not recruiting, Numab Therapeutics AG | Recruiting --> Active, not recruiting
    Enrollment closed
    7ms
    Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, University of California, San Diego | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • zilovertamab (UC-961)